Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| moderate |
LUCENTIS 10 mg/mL, solution for injection provides a moderate improvement in actual benefit (level III) in terms of efficacy in comparison with VISUDYNE in the treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia. |
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
dnGEgLqbNu9RgZgB
